ADPT
HEALTHCAREAdaptive Biotechnologies Corp
$14.43+0.65 (+4.72%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ADPT Today?
No stock-specific AI insight has been generated for ADPT yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.50$20.76
$14.43
Fundamentals
Market Cap$2.3B
P/E Ratio—
EPS$-0.32
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin-0.2%
Debt / Equity—
Trading
Volume4.9M
Avg Volume (10D)—
Shares Outstanding160.0M
ADPT News
20 articles- Adaptive Biotechnologies (ADPT) Q1 Earnings: Taking a Look at Key Metrics Versus EstimatesYahoo Finance·May 5, 2026
- Adaptive Biotechnologies Q1 Earnings Call HighlightsMarketbeat·May 5, 2026
- Adaptive Biotechnologies (ADPT) Reports Q1 Loss, Beats Revenue EstimatesYahoo Finance·May 5, 2026
- Adaptive Biotechnologies Reports First Quarter 2026 Financial ResultsYahoo Finance·May 5, 2026
- Adaptive Biotechnologies' Chief Operating Officer Sold Over 19,000 Company Shares. Here's What That Means for Investors.Motley Fool·May 4, 2026
- How The Investment Story For Adaptive Biotechnologies (ADPT) Is Shifting With New Street AssumptionsYahoo Finance·May 3, 2026
- Adaptive Biotechnologies' COO Is Running a Systematic Sell Program — Here's What It MeansMotley Fool·Apr 20, 2026
- Should You Sell Adaptive Biotechnologies (ADPT) After Its President and COO Sold 57,000 Shares?The Motley Fool·Apr 18, 2026
- Adaptive Biotechnologies to Report First Quarter 2026 Financial Results on May 5, 2026Yahoo Finance·Apr 15, 2026
- Adaptive Biotech Insider Sells $554K as Revenue Jumps 55%, but Here's What Investors Should Focus OnThe Motley Fool·Apr 8, 2026
- A Look At Adaptive Biotechnologies (ADPT) Valuation After Q4 2025 Beat And New Pfizer AgreementsYahoo Finance·Apr 5, 2026
- Adaptive Biotech's President Trimmed Her Position. But what Remains is worth a lookThe Motley Fool·Mar 31, 2026
- Adaptive Biotech Insider Sale of 180,000 Shares Tied to Tax Event as Stock Jumps 70% in a YearThe Motley Fool·Mar 26, 2026
- Adaptive Biotechnologies Insider Sells $1 Million in Stock After a Doubling in Share PriceMotley Fool·Mar 26, 2026
- Adaptive Biotechnologies (ADPT) Moves 5.8% Higher: Will This Strength Last?Yahoo Finance·Mar 16, 2026
- Insider Sales Put Focus On Adaptive Biotechnologies Growth Story And Dilution RiskYahoo Finance·Mar 6, 2026
- Slingshot Biosciences Appoints Jim Snook as Senior Vice President, Global SalesYahoo Finance·Mar 5, 2026
- Adaptive Biotechnologies CEO Flags MRD Momentum, Lifts 2025 Volume Outlook to 30%+ at TD Cowen Conf.Marketbeat·Mar 3, 2026
- Why are Analysts Optimistic About Adaptive Biotechnologies (ADPT)?Yahoo Finance·Feb 28, 2026
- TD Cowen is Bullish on Adaptive Biotechnologies Corporation (ADPT)Yahoo Finance·Feb 21, 2026
All 20 articles loaded
Price Data
Open$14.64
Previous Close$13.78
Day High$14.98
Day Low$12.98
52 Week High$20.76
52 Week Low$8.50
52-Week Range
$8.50$20.76
$14.43
Fundamentals
Market Cap$2.3B
P/E Ratio—
EPS$-0.32
Dividend Yield—
Dividend / Share—
ROE-0.3%
Profit Margin-0.2%
Debt / Equity—
Trading
Volume4.9M
Avg Volume (10D)—
Shares Outstanding160.0M
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company is headquartered in Seattle, Washington.
HEALTHCAREDIAGNOSTICS & RESEARCH
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICDIAGNOSTICS & RESEARCH
CIK—
Composite FIGI—
Share Class FIGI—